Rituximab and bilateral HSV epithelial keratitis in a patient with mucous membrane pemphigoid.

Background B cell depleting therapy is widely used for lymphoproliferative diseases and immune-mediated disorders, including mucous membrane pemphigoid. The latter is an autoimmune blistering disease affecting predominantly the mucosae potentially associated with devastating complications.